SciELO - Scientific Electronic Library Online

vol.28 número4Prevalencia del Intervalo QT Prolongado en diferentes patrones electrocardiográficos: Estudio por TeleelectrocardiografíaLa edad como factor determinante en la decisión para utilizar la terapia de anticoagulación oral: una auditoria de gestión clínica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista chilena de cardiología

versión On-line ISSN 0718-8560


CAORSI S, Carlos; BARRA R, Victoria; KAUFFMANN Q, Ronald  y  PINEDA A, Fernando. New generation of biocompatible polymer coated stents: immediate and follow-up results in 52 patients. Rev Chil Cardiol [online]. 2009, vol.28, n.4, pp.357-362. ISSN 0718-8560.

Background: a new generation of drug-eluting stents (DES) coated with a non-thrombogenic and biocompatible polymer allows a fast re-epithelization, reducing inflammation and maintaining endothelial function of the vascular wall. Therefore, not only the anti-proliferative effect of the drug contained in DES determines the response of the vascular wall, but also the polymer biocompatibility seems to play a fundamental role. Aim: to evaluate the results and clínica! follow up of patients submitted to elective coronary angioplasty using a biocompatible polymer coated DES. Method: 52 patients treated with DES were followed from 3 to 15 months (mean 8.6 months) after stent implantation. Overall MACE defined as, death, myocardial infarction, emergent cardiac surgery or repeat revascularization of the target lesion (TLR) was evaluated at 30 days, 3, 6, 9 and 12 months. Stent thrombosis was also evaluated at 0-30 days (early), 31-360 days (late), and more than 361 days (very late). Results: Mean age was 63.8 ± 10.8 years; hypertension was present in 71.1%, diabetes in 17,3%, hyperlipidemia in 50%, and 28.8% were current smokers. Two or three vessel diseases were present in 65.3% of patients: lesions were present in the LAD in 51.9%. Lesions were classified as B-2 or C (according to American Heart Association) in 61.2% of cases. Pre procedure reference vessel diameter (RVD) was 3.0 ± 0.6 mm, with a mi ni mu m luminal diameter (MLD) of 0.8 ± 0.5 mm, percentage stenosis of 77.2 ± 17.9% and lesion length averaged 14 ± 8.3 mm. Both device and procedure success rates were 98.1%. During follow up MACE occurred in 3.8% and no stent thrombosis were registered. Conclusión: During the study period, the observed procedure related MACE rate was low, with no instances of probable, possible, or definitive stent thrombosis. The clinical results confirmed the good performance and security of this biocompatible polymer containing stent.

Palabras clave : Drug eluting stents; biocompatible polymer stents.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons